Journal of Clinical and Translational Hepatology

Journal Information
ISSN / EISSN : 2225-0719 / 2310-8819
Current Publisher: Xia & He Publishing Inc. (10.14218)
Total articles ≅ 355
Current Coverage
PUBMED
PMC
ESCI
Archived in
SHERPA/ROMEO
Filter:

Latest articles in this journal

Sean P. Tighe, Daud Akhtar, Umair Iqbal, Aijaz Ahmed
Journal of Clinical and Translational Hepatology, Volume 8, pp 1-5; doi:10.14218/jcth.2020.00012

Abstract:
Chronic liver disease (CLD) is an under-recognized epidemic that continues to increase in prevalence and is a major health concern. Silymarin, the active compound of Silybum marianum (Milk thistle), has historically been used in CLD. A significant barrier to silymarin use is its poor bioavailability. Attempts at improving the bioavailability of silymarin have led to a better understanding of formulation methods, pharmacokinetics, dosing, and associated drug interactions. Clinically, silymarin exerts its hepatoprotective effects through antioxidative, antifibrotic, anti-inflammatory, antitoxin, and anticancerous mechanisms of actions. Despite the use of silymarin being extensively studied in alcoholic liver disease, metabolic-associated fatty liver disease, viral hepatitis, and drug-induced liver injury, the overall efficacy of silymarin remains unclear and more research is warranted to better elucidate the role of silymarin in CLD, specifically regarding its anti-inflammatory effects. Here, we review the current biochemical and clinical evidence regarding silymarin in CLD.
Sarah Altajar, Gyorgy Baffy
Journal of Clinical and Translational Hepatology, Volume 8, pp 1-10; doi:10.14218/jcth.2020.00065

Abstract:
The association between the pathogenesis and natural course of nonalcoholic fatty liver disease (NAFLD) and skeletal muscle dysfunction is increasingly recognized. These obesity-associated disorders originate primarily from sustained caloric excess, gradually disrupting cellular and molecular mechanisms of the adipose–muscle–liver axis resulting in end-stage tissue injury exemplified by cirrhosis and sarcopenia. These major clinical phenotypes develop through complex organ–tissue interactions from the earliest stages of NAFLD. While the role of adipose tissue expansion and remodeling is well established in the development of NAFLD, less is known about the specific interplay between skeletal muscle and the liver in this process. Here, the relationship between skeletal muscle and liver in various stages of NAFLD progression is reviewed. Current knowledge of the pathophysiology is summarized with the goal of better understanding the natural history, risk stratification, and management of NAFLD.
Xin Yan, Wenwen Jin, Jie Zhang, Mengke Wang, Shousheng Liu, Yongning Xin
Journal of Clinical and Translational Hepatology, Volume 8, pp 1-6; doi:10.14218/jcth.2020.00071

Abstract:
Background and Aims: Coronary artery disease (CAD) is a major cause of morbidity and mortality in patients with non-alcoholic fatty liver disease (NAFLD). Previous studies have suggested that TCF7L2 rs7903146 was related to the risk of developing NAFLD but the conclusions are not consistent and no related study has been conducted in Chinese populations. The aim of this study was to investigate the association between TCF7L2 rs7903146 and the risk of developing NAFLD and CAD in a Chinese Han population.
Joseph K Lim, Alex Y Chang, Atif Zaman, Paul Martin, Conrado M Fernandez-Rodriguez, Mete Korkmaz, Simona Rossi, James M Ford, Tamara Noonan, Elizabeth Cooney, et al.
Journal of Clinical and Translational Hepatology, Volume 8, pp 1-8; doi:10.14218/jcth.2020.00039

Catherine Choi, Youssef Botros, Jamil Shah, Pei Xue, Anja Jones, Mark Galan, Raquel Olivo, Mumtaz Niazi, Flavio Paterno, James Guarrera, et al.
Journal of Clinical and Translational Hepatology, Volume 8, pp 1-4; doi:10.14218/jcth.2020.00062

Abstract:
Direct-acting antiviral (DAA) therapy is often well-tolerated, and adverse events from DAA therapy are uncommon. We report a case of a woman who underwent orthotopic liver transplant for chronic hepatitis C infection and later developed alloimmune hepatitis shortly after starting DAA therapy for recurrent hepatitis C infection. The patient developed acute alloimmune hepatitis approximately 2 weeks after starting treatment with sofosbuvir, velpatasvir, and voxilaprevir. This case report proposes a dysregulation of immune surveillance due to the DAA stimulation of host immunity and rapid elimination of hepatitis C viral load as a precipitating factor for the alloimmune process, leading to alloimmune hepatitis in a post-transplant patient who starts on DAA.
Ashok Choudhury, Golamari Srinivasa Reddy, Shantan Venishetty, Viniyendra Pamecha, Saggere Muralikrishna Shasthry, Arvind Tomar, Lalita Gauri Mitra, Venkata Siva Tez Prasad, Rajendra Prasad Mathur, Debajyoti Bhattacharya, et al.
Journal of Clinical and Translational Hepatology, Volume 8, pp 1-7; doi:10.14218/jcth.2020.00061

Abstract:
The severe acute respiratory syndrome corona virus-2 (referred to as SARS CoV2) pandemic had a great impact on public life in general as well as on populations with pre-existing disease and co-morbidities. Liver transplant and immunosuppressant medication predisposes to more severe disease and is often associated with poor outcome. The clinical features, disease course, treatment and process of modulating the immunosuppression is challenging. Here, we describe the clinical presentation, treatment and outcomes in six liver transplant recipients. Out of those six patients, three had mild, one had moderate and one had severe COVID-19, and one was asymptomatic. The immunosuppression minimization or withdrawal was done based upon the clinical severity. Consideration of tocilizumab and/o convalescent plasma as well as antivirals i.e. remdesvir done in severe cases. The routine practice of prophylactic anticoagulation, consideration of repurposed drugs (i.e. teicoplanin and doxycycline), and watchful monitoring of asymptomatic recipients helped to achieve an uneventful recovery.
Ahyoung Kim, Bolin Niu, Tinsay Woreta, Po-Hung Chen
Journal of Clinical and Translational Hepatology, Volume 8, pp 1-7; doi:10.14218/jcth.2020.00058

Abstract:
Acute liver failure (ALF) is the rapid onset of severe liver dysfunction, defined by the presence of hepatic encephalopathy and impaired synthetic function (international normalized ratio of ≥1.5) in the absence of underlying liver disease. The elevated international normalized ratio value in ALF is often misinterpreted as an increased hemorrhagic tendency, which can lead to inappropriate, prophylactic transfusions of blood products. However, global assessments of coagulopathy via viscoelastic tests or thrombin generation assay suggest a reestablished hemostatic, or even hypercoagulable, status in patients with ALF. Although the current versions of global assays are not perfect, they can provide more nuanced insights into the hemostatic system in ALF than the conventional measures of coagulopathy.
Yujia Li, Shilin Li, Xiaoqiong Duan, Chunhui Yang, Min Xu, Limin Chen
Journal of Clinical and Translational Hepatology, Volume 8, pp 1-8; doi:10.14218/jcth.2020.00046

Abstract:
Globally, hepatitis B virus (HBV) infection and its related liver diseases account for 780,000 deaths every year. Outcomes of HBV infection depend on the interaction between the virus and host immune system. It is becoming increasingly apparent that Kupffer cells (KCs), the largest population of resident and monocyte-derived macrophages in the liver, contribute to HBV infection in various aspects. These cells play an important role not only in the anti-HBV immunity including virus recognition, cytokine production to directly inhibit viral replication and recruitment and activation of other immune cells involved in virus clearance but also in HBV outcome and progression, such as persistent infection and development of end-stage liver diseases. Since liver macrophages play multiple roles in HBV infection, they are directly targeted by HBV to benefit its life cycle. In the present review, we briefly outline the current advances of research of macrophages, especially the studies of their phenotypes, in chronic HBV infection.
Qiuli Xie, Yingen Feng, Jing Li, Xiaoqiao Chen, Jianqiang Ding
Journal of Clinical and Translational Hepatology, Volume 8, pp 1-2; doi:10.14218/jcth.2020.00038

Khalid Alsawat, Almoutaz Hashim, Mohamed Alboraie, Yasser Fouad
Journal of Clinical and Translational Hepatology, Volume 8, pp 1-2; doi:10.14218/jcth.2020.00049

Back to Top Top